Neurocrine Biosciences Company Profile (NASDAQ:NBIX)

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NBIX
  • CUSIP: 64125C10
  • Web:
  • Market Cap: $5.39 billion
  • Outstanding Shares: 88,222,000
Average Prices:
  • 50 Day Moving Avg: $58.73
  • 200 Day Moving Avg: $51.36
  • 52 Week Range: $37.35 - $63.77
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -35.96
  • P/E Growth: 1.87
Sales & Book Value:
  • Annual Revenue: $6.34 million
  • Price / Sales: 850.77
  • Book Value: $3.91 per share
  • Price / Book: 15.64
  • EBITDA: ($219,960,000.00)
  • Return on Equity: -69.86%
  • Return on Assets: -48.65%
  • Debt-to-Equity Ratio: 1.04%
  • Current Ratio: 19.36%
  • Quick Ratio: 19.36%
  • Average Volume: 840,239 shs.
  • Beta: 0.41
  • Short Ratio: 11.78

Frequently Asked Questions for Neurocrine Biosciences (NASDAQ:NBIX)

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.01. The firm had revenue of $6.34 million for the quarter, compared to the consensus estimate of $0.61 million. During the same period last year, the company earned ($0.46) earnings per share. View Neurocrine Biosciences' Earnings History.

When will Neurocrine Biosciences make its next earnings announcement?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Neurocrine Biosciences.

Where is Neurocrine Biosciences' stock going? Where will Neurocrine Biosciences' stock price be in 2017?

17 brokers have issued 12-month target prices for Neurocrine Biosciences' shares. Their forecasts range from $55.00 to $100.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $68.81 in the next year. View Analyst Ratings for Neurocrine Biosciences.

What are analysts saying about Neurocrine Biosciences stock?

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:

  • 1. Cowen and Company analysts commented, "NBIX remains well funded, ending Q4 with $352MM in cash." (2/15/2017)
  • 2. Robert W. Baird analysts commented, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly beating estimates on lower-than-expected opex. Though we are only a few weeks into 2017, it has already been a busy year for NBIX. Expect the year to continue to bring multiple updates, from potential approval of Ingrezza in TD and Tourette data in May to Phase 3 UF data for elagolix near year-end, an elagolix NDA submission, advances in CAH and essential tremor, and FDA discussions on newly licensed opicapone' Earnings and spend in-line, expect accelerations into launch. 4Q16 EPS of ($0.51) modestly beat our/consensus estimates of ($0.54)/($0.57), respectively, due to lower than projected operating expenses. Looking ahead to 2017, management expects opex to increase to about $230M-$240M due activities surrounding the launch of Ingrezza." (2/15/2017)
  • 3. Needham & Company LLC analysts commented, "Company continues to prepare for Ingrezza launch ahead of 4/11/17 PDUFA date. We expect approval based on strength of Phase 3 data, followed by launch ~6wks later. We believe Boxed Warning/ REMS are possible. Phase 2 pediatric Tourette Syndrome (TS) data are expected May 2017 (was Apr). Given efficacy trend observed in adult Phase 2 TS, we believe Ingrezza will likely be active in pediatric TS as well. Elagolix NDA submission for Endometriosis by Abbvie is expected 3Q17 (was 2H17), triggering a $30M payment to Neurocrine. Phase 3 results in Uterine Fibroids are expected by YE17. We believe stock is attractive ahead of near term events. BUY." (2/10/2017)
  • 4. HC Wainwright analysts commented, "We expect FDA to agree in early 2017 that Atara has demonstrated comparability between clinical batches of ATA-129, or EBV-CTL, and the prior material produced at MSKCC, paving the way for Phase 3 start. We believe comparability data will include the number of cells to administer, cytoreactivity, cell storage time, restriction studies (HLA types), variability based on release criteria, and the methods by which data are collected. CMC amendment standard for new clinical material Importantly, a CMC amendment is standard practice for an IND when new clinical material is introduced; therefore, we view Atara’s process as normal." (1/18/2017)
  • 5. Jefferies Group LLC analysts commented, "While the study showed a stat sig improvement on the Clinical Global Impression of Change scale (CGI; p=0.015), the study did not reach stat sig on the 1EP of Yale Global Tic Severity Scale (YGTSS; p=0.18). No further trial details were released. Although a setback, we note that this does not directly read through to the pediatric study readout expected in April." (1/18/2017)

Who are some of Neurocrine Biosciences' key competitors?

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:

  • William H. Rastetter Ph.D., Independent Chairman of the Board
  • David-Alexandre C. Gros M.D., President, Interim Chief Financial Officer, Chief Operating Officer
  • Kevin C. Gorman Ph.D., Chief Executive Officer, Director
  • Eric S. Benevich, Chief Commercial Officer
  • Haig P. Bozigian Ph.D., Chief Development Officer
  • Julie Cooke, Chief People Officer
  • Kyle Gano Ph.D., Chief Business Development Officer
  • Dimitri E. Grigoriadis Ph.D., Chief Research Officer
  • Malcolm Lloyd-Smith, Chief Regulatory Officer
  • Christopher F. O'Brien M.D., Chief Medical Officer

Who owns Neurocrine Biosciences stock?

Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include PERCEPTIVE ADVISORS LLC (5.30%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

How do I buy Neurocrine Biosciences stock?

Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of Neurocrine Biosciences stock can currently be purchased for approximately $61.14.

MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)
Community Ranking:  4.3 out of 5 (star star star star)
Outperform Votes:  551 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  643
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neurocrine Biosciences (NASDAQ:NBIX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 16 Buy Ratings
Consensus Rating:Buy (Score: 2.94)
Consensus Price Target: $68.81 (12.55% upside)
Consensus Price Target History for Neurocrine Biosciences (NASDAQ:NBIX)
Price Target History for Neurocrine Biosciences (NASDAQ:NBIX)
Analysts' Ratings History for Neurocrine Biosciences (NASDAQ:NBIX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/10/2017Leerink SwannReiterated RatingOutperform$67.00 -> $72.00N/AView Rating Details
10/5/2017BMO Capital MarketsReiterated RatingOutperform$84.00N/AView Rating Details
10/3/2017Jefferies Group LLCReiterated RatingBuy$66.00 -> $69.00LowView Rating Details
9/21/2017Robert W. BairdReiterated RatingOutperform$66.00HighView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$58.00LowView Rating Details
9/7/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$70.00LowView Rating Details
8/24/2017Piper Jaffray CompaniesSet Price TargetBuy$68.00MediumView Rating Details
8/9/2017Cowen and CompanyReiterated RatingOutperform$60.00 -> $65.00MediumView Rating Details
5/24/2017J P Morgan Chase & CoSet Price TargetBuy$57.00MediumView Rating Details
5/15/2017Bank of America CorporationReiterated RatingBuy$70.00MediumView Rating Details
5/2/2017Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00LowView Rating Details
3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/AView Rating Details
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 -> $100.00N/AView Rating Details
2/10/2017ICAPReiterated RatingOutperform$55.00N/AView Rating Details
1/27/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
1/19/2017Deutsche Bank AGReiterated RatingBuy$65.00 -> $62.00N/AView Rating Details
11/22/2016Citigroup Inc.Initiated CoverageMarket Perform$55.00N/AView Rating Details
11/2/2015NomuraBoost Price TargetBuy$34.00 -> $43.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)
Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Earnings History by Quarter for Neurocrine Biosciences (NASDAQ NBIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.49)N/AView Earnings Details
8/3/2017Q2 17($0.67)($0.68)$0.61 million$6.34 millionViewListenView Earnings Details
5/9/2017Q1 17($0.67)($0.90)$3.00 millionViewListenView Earnings Details
2/14/2017Q416($0.55)($0.51)$4.55 millionViewListenView Earnings Details
11/2/2016Q316($0.57)($0.43)ViewN/AView Earnings Details
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)$0.78 millionViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Neurocrine Biosciences (NASDAQ:NBIX)
2017 EPS Consensus Estimate: ($2.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.89)($0.54)($0.65)
Q2 20174($0.68)($0.61)($0.65)
Q3 20174($0.72)($0.28)($0.53)
Q4 20174($0.64)($0.28)($0.43)
(Data provided by Zacks Investment Research)


Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Neurocrine Biosciences (NASDAQ:NBIX)
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 96.27%
Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Christopher Flint ObrienInsiderSell6,925$61.04$422,702.00View SEC Filing  
9/6/2017Haig P BozigianInsiderSell26,250$60.00$1,575,000.00View SEC Filing  
9/5/2017Christopher Flint ObrienInsiderSell52,817$57.50$3,036,977.50View SEC Filing  
8/9/2017Dimitri E GrigoriadisInsiderSell15,354$55.00$844,470.00View SEC Filing  
8/4/2017Haig P BozigianInsiderSell22,500$50.00$1,125,000.00View SEC Filing  
7/27/2017Christopher Flint ObrienInsiderSell8,734$50.00$436,700.00View SEC Filing  
5/23/2017Dimitri E GrigoriadisInsiderSell10,000$53.39$533,900.00View SEC Filing  
5/19/2017Malcolm Lloyd-SmithInsiderSell9,960$53.63$534,154.80View SEC Filing  
5/5/2017Corinne H NevinnyDirectorSell5,000$53.98$269,900.00View SEC Filing  
5/2/2017Dimitri E GrigoriadisInsiderSell10,000$55.00$550,000.00View SEC Filing  
5/2/2017Kevin Charles GormanCEOSell21,739$53.23$1,157,166.97View SEC Filing  
5/1/2017Kyle GanoInsiderSell15,000$54.00$810,000.00View SEC Filing  
4/12/2017Haig P BozigianInsiderSell13,065$50.42$658,737.30View SEC Filing  
4/12/2017Kevin Charles GormanCEOSell19,596$50.42$988,030.32View SEC Filing  
2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76View SEC Filing  
2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51View SEC Filing  
2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80View SEC Filing  
2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82View SEC Filing  
2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.00View SEC Filing  
2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75View SEC Filing  
2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.00View SEC Filing  
1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75View SEC Filing  
1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50View SEC Filing  
1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50View SEC Filing  
1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.50View SEC Filing  
1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00View SEC Filing  
11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.00View SEC Filing  
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.00View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.00View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.00View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.00View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.40View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.00View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.00View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.00View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.00View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.00View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.00View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.00View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.96View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.75View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.70View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.00View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.35View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Neurocrine Biosciences (NASDAQ:NBIX)
Latest Headlines for Neurocrine Biosciences (NASDAQ:NBIX)
DateHeadline logoHow Is Neurocrine Biosciences Positioned Now? - October 17 at 2:03 AM logoQ3 2017 Earnings Estimate for Neurocrine Biosciences, Inc. Issued By Leerink Swann (NBIX) - October 12 at 8:02 AM logoNeurocrine Biosciences, Inc. (NBIX) Price Target Raised to $72.00 - October 10 at 9:14 AM logoNeurocrine Biosciences, Inc. (NBIX) Rating Reiterated by BMO Capital Markets - October 8 at 6:34 AM logoNeurocrine Biosciences, Inc. (NBIX) Given Consensus Recommendation of "Buy" by Analysts - October 7 at 4:52 AM logo$25.17 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter - October 6 at 10:40 AM logoNeurocrine Biosciences (NBIX) Granted FDA Approval of 80 mg INGREZZA (valbenazine) Capsules - - October 6 at 9:42 AM logoNeurocrine Biosciences, Inc. (NBIX) Forecasted to Earn FY2018 Earnings of ($1.31) Per Share - October 5 at 12:58 PM logoNeurocrine Announces FDA Approval Of 80 Mg Capsule Of INGREZZA - Quick Facts - October 5 at 10:28 AM logoNeurocrine stock up 3% on higher-dose approval of tardive dyskinesia drug - October 5 at 10:28 AM logoNeurocrine Biosciences (NBIX) Granted FDA Approval of 80 mg INGREZZA (valbenazine) Capsules - October 5 at 10:28 AM logoNeurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD) - October 5 at 10:28 AM logoUPDATED: Neurocrine stock up 3% on higher-dose approval of tardive dyskinesia drug - October 5 at 10:28 AM logoNeurocrine Biosciences, Inc. (NBIX) Insider Sells $422,702.00 in Stock - October 3 at 10:52 PM logoJefferies Group LLC Raises Neurocrine Biosciences, Inc. (NBIX) Price Target to $69.00 - October 3 at 9:14 AM logoBiotech Investors, Here's Your PDUFA Primer For October - Benzinga - September 28 at 12:43 PM logoStocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 91 - September 22 at 10:39 AM logoToday's Research Reports on Stocks to Watch: Neurocrine Biosciences and Biocryst Pharmaceuticals - September 22 at 10:39 AM logoNeurocrine Biosciences, Inc. (NBIX) Receives Outperform Rating from Robert W. Baird - September 21 at 6:22 PM logoNeurocrine Biosciences, Inc. (NBIX) Given "Buy" Rating at Needham & Company LLC - September 17 at 8:48 AM logoNeurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the ... - PR Newswire (press release) - September 16 at 11:51 PM logoNeurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress - September 16 at 6:52 AM logoEQAL's Underlying Holdings Imply 10% Gain Potential - September 14 at 8:08 AM logoNeurocrine Biosciences, Inc. (NBIX) Receives Consensus Recommendation of "Buy" from Analysts - September 12 at 4:40 AM logoInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 26,250 Shares of Stock - September 8 at 4:22 PM logoChristopher Flint Obrien Sells 52,817 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock - September 7 at 7:20 PM logoNeurocrine Biosciences' (NBIX) "Buy" Rating Reiterated at Oppenheimer Holdings, Inc. - September 7 at 3:26 PM logoNeurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference - PR Newswire (press release) - September 7 at 6:37 AM logoNeurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference - September 7 at 6:37 AM logoInteresting NBIX Put And Call Options For October 20th - Nasdaq - August 31 at 7:41 AM logoStocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 82 - August 31 at 7:40 AM logoNeurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference - August 31 at 7:40 AM logoToday's Research Reports on Trending Tickers: Portola Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. - August 25 at 8:59 AM logoNeurocrine Biosciences, Inc. (NBIX) PT Set at $68.00 by Piper Jaffray Companies - August 24 at 6:28 PM logoNeurocrine Biosciences, Inc. (NBIX) Receives Average Rating of "Buy" from Brokerages - August 18 at 4:40 AM logoNeurocrine Biosciences: Ingrezza's Strong Launch, Pipeline To Create Value - Seeking Alpha - August 17 at 8:51 PM logoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc. - August 15 at 2:45 AM logoNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Dimitri E. Grigoriadis Sells 15,354 Shares - August 14 at 1:27 PM logoIHS Markit Score downgrades Neurocrine Biosciences Inc to 12 out of 100, ranking negatively in two out of three available IHS Markit categories. - August 12 at 6:08 AM logo$24.60 Million in Sales Expected for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) This Quarter - August 11 at 5:56 PM logoNeurocrine Biosciences Inc - August 11 at 6:46 AM logoFeatured Company News - Mylan Launches Avonza(TM) in India - August 11 at 6:46 AM logoIHS Markit Score upgrades Neurocrine Biosciences Inc to 34 out of 100, despite ranking positively in only one IHS Markit category. - August 11 at 6:46 AM logo-$0.49 Earnings Per Share Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter - August 9 at 2:12 PM logoInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 22,500 Shares of Stock - August 8 at 7:44 PM logoNeurocrine Biosciences, Inc. to Post FY2019 Earnings of $0.13 Per Share, Jefferies Group Forecasts (NASDAQ:NBIX) - August 7 at 9:56 AM logoNeurocrine Biosciences Off To A Good Start With Ingrezza - Seeking Alpha - August 6 at 5:58 AM logoNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Announces Quarterly Earnings Results - August 5 at 8:22 PM logoEdited Transcript of NBIX earnings conference call or presentation 3-Aug-17 9:00pm GMT - August 4 at 10:08 PM logoNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target Raised to $84.00 at BMO Capital Markets - August 4 at 4:16 PM



Neurocrine Biosciences (NBIX) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.